Ayvakyt

RSS

avapritinib

Authorised
This medicine is authorised for use in the European Union.

Overview

Ayvakyt is a cancer medicine used to treat gastrointestinal stromal tumour (GIST), a cancer of the stomach and bowel, that cannot be removed by surgery and has spread to other parts of the body. Ayvakyt is used when the cancer cells have a D842V mutation, a change in the gene for the platelet-derived growth factor receptor alpha (PDGFRA).

GIST is rare, and Ayvakyt was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 July 2017.

This EPAR was last updated on 06/11/2020

Authorisation details

Product details
Name
Ayvakyt
Agency product number
EMEA/H/C/005208
Active substance
avapritinib
International non-proprietary name (INN) or common name
avapritinib
Therapeutic area (MeSH)
Gastrointestinal Stromal Tumors
Anatomical therapeutic chemical (ATC) code
L01EX18
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

OrphanOrphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Blueprint Medicines (Netherlands) B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
24/09/2020
Contact address

Gustav Mahlerplein 2
Amsterdam
Netherlands

Product information

15/10/2020 Ayvakyt - EMEA/H/C/005208 - IAIN/0001/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Other antineoplastic agents

  • Protein kinase inhibitors

Therapeutic indication

Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.

Assessment history

How useful was this page?

Add your rating
Average
1 rating